Detalles de la búsqueda
1.
Population pharmacokinetic modelling of tremelimumab in patients with advanced solid tumours and the impact of disease status on time-varying clearance.
Br J Clin Pharmacol
; 89(5): 1601-1616, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36454221
2.
Physiologically Based Absorption Modelling to Explore the Formulation and Gastric pH Changes on the Pharmacokinetics of Acalabrutinib.
Pharm Res
; 40(2): 375-386, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-35478298
3.
Acalabrutinib CYP3A-mediated drug-drug interactions: Clinical evaluations and physiologically based pharmacokinetic modelling to inform dose adjustment strategy.
Br J Clin Pharmacol
; 88(8): 3716-3729, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35165925
4.
Selecting the dosage of ceftazidime-avibactam in the perfect storm of nosocomial pneumonia.
Eur J Clin Pharmacol
; 76(3): 349-361, 2020 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-31836928
5.
Physiologically based pharmacokinetic modeling to predict exposures in healthy Japanese subjects with different CYP2C19 phenotypes: Esomeprazole case studyâ©.
Int J Clin Pharmacol Ther
; 58(1): 29-36, 2020 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-31657713
6.
Population pharmacokinetic analysis of esomeprazole in Japanese subjects with various CYP2C19 phenotypes.
J Clin Pharm Ther
; 45(5): 1030-1038, 2020 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-32227647
7.
Ceftaroline fosamil doses and breakpoints for Staphylococcus aureus in complicated skin and soft tissue infections.
J Antimicrob Chemother
; 74(2): 425-431, 2019 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30380060
8.
Population pharmacokinetic analysis of danvatirsen supporting flat dosing switch.
J Pharmacokinet Pharmacodyn
; 46(1): 65-74, 2019 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-30661177
9.
Simplified Aztreonam Dosing in Patients with End-Stage Renal Disease: Results of a Monte Carlo Simulation.
Antimicrob Agents Chemother
; 62(11)2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30150467
10.
Population pharmacokinetics of the MEK inhibitor selumetinib and its active N-desmethyl metabolite: data from 10 phase I trials.
Br J Clin Pharmacol
; 84(1): 52-63, 2018 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-28833380
11.
Development of a physiologically based pharmacokinetic model to predict the effects of flavin-containing monooxygenase 3 (FMO3) polymorphisms on itopride exposure.
Biopharm Drug Dispos
; 38(6): 389-393, 2017 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-28255999
12.
Phase I Study Assessing the Pharmacokinetic Profile, Safety, and Tolerability of a Single Dose of Ceftazidime-Avibactam in Hospitalized Pediatric Patients.
Antimicrob Agents Chemother
; 60(10): 6252-9, 2016 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-27503642
13.
Pharmacokinetics, metabolism and excretion of [(14)C]-lanicemine (AZD6765), a novel low-trapping N-methyl-d-aspartic acid receptor channel blocker, in healthy subjects.
Xenobiotica
; 45(3): 244-55, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25259653
14.
Physiologically based pharmacokinetic modeling to predict complex drug-drug interactions: a case study of AZD2327 and its metabolite, competitive and time-dependent CYP3A inhibitors.
Biopharm Drug Dispos
; 36(8): 507-19, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26081137
15.
Development of physiologically based pharmacokinetic model to evaluate the relative systemic exposure to quetiapine after administration of IR and XR formulations to adults, children and adolescents.
Biopharm Drug Dispos
; 35(6): 341-52, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-24797229
16.
Clinical Pharmacology Strategies for Bispecific Antibody Development: Learnings from FDA-Approved Bispecific Antibodies in Oncology.
Clin Pharmacol Ther
; 2024 Jun 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38825990
17.
Modeling of Proliferating CD4 and CD8 T-Cell Changes to Tremelimumab Exposure in Patients with Unresectable Hepatocellular Carcinoma.
Clin Pharmacol Ther
; 114(4): 874-882, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37422678
18.
Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma.
Clin Cancer Res
; 29(4): 754-763, 2023 02 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-36477555
19.
Population Pharmacokinetics and Exposure-Response Analysis of Tremelimumab 300 mg Single Dose Combined with Durvalumab 1500 mg Q4W (STRIDE) in Patients with Unresectable Hepatocellular Carcinoma.
J Clin Pharmacol
; 63(11): 1221-1231, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37300457
20.
Population Pharmacokinetics and Exposure-Response Analysis for the CTLA-4 Inhibitor Tremelimumab in Metastatic NSCLC Patients in the Phase III POSEIDON Study.
Clin Pharmacol Ther
; 114(6): 1375-1386, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37777827